Compare UG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | MCRB |
|---|---|---|
| Founded | 1942 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 41.2M |
| IPO Year | 1995 | 2015 |
| Metric | UG | MCRB |
|---|---|---|
| Price | $6.71 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 10.5K | ★ 67.2K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 7.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $2.26 |
| 52 Week High | $8.45 | $29.98 |
| Indicator | UG | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 19.04 |
| Support Level | $6.61 | N/A |
| Resistance Level | $7.50 | $9.53 |
| Average True Range (ATR) | 0.24 | 0.20 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 30.82 | 9.00 |
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.